The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
PR Newswire —
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a...